1.09%
1.43%
-4.91%
-11.89%
-0.63%
-48.93%
-23.77%
AI Spotlight on PFE
Company Description
Pfizer Inc.discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products worldwide.It offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic and women's health under the Premarin family and Eliquis brands; biologics, small molecules, immunotherapies, and biosimilars under the Ibrance, Xtandi, Sutent, Inlyta, Retacrit, Lorbrena, and Braftovi brands; and sterile injectable and anti-infective medicines, and oral COVID-19 treatment under the Sulperazon, Medrol, Zavicefta, Zithromax, Vfend, Panzyga, and Paxlovid brands.
The company also provides medicines and vaccines in various therapeutic areas, such as pneumococcal disease, meningococcal disease, tick-borne encephalitis, and COVID-19 under the Comirnaty/BNT162b2, Nimenrix, FSME/IMMUN-TicoVac, Trumenba, and the Prevnar family brands; biosimilars for chronic immune and inflammatory diseases under the Xeljanz, Enbrel, Inflectra, Eucrisa/Staquis, and Cibinqo brands; and amyloidosis, hemophilia, and endocrine diseases under the Vyndaqel/Vyndamax, BeneFIX, and Genotropin brands.In addition, the company is involved in the contract manufacturing business.It serves wholesalers, retailers, hospitals, clinics, government agencies, pharmacies, and individual provider offices, as well as disease control and prevention centers.
The company has collaboration agreements with Bristol-Myers Squibb Company; Astellas Pharma US, Inc.; Myovant Sciences Ltd.; Akcea Therapeutics, Inc; Merck KGaA; Valneva SE; BioNTech SE; and Arvinas, Inc.Pfizer Inc.was founded in 1849 and is headquartered in New York, New York.
Market Data
| Last Price | 26.91 |
| Change Percentage | 1.09% |
| Open | 26.66 |
| Previous Close | 26.62 |
| Market Cap ( Millions) | 152499 |
| Volume | 26760677 |
| Year High | 31.54 |
| Year Low | 24.48 |
| M A 50 | 26.08 |
| M A 200 | 27.87 |
Financial Ratios
| FCF Yield | 5.39% |
| Dividend Yield | 6.28% |
| ROE | 4.72% |
| Debt / Equity | 72.19% |
| Net Debt / EBIDTA | 473.62% |
| Price To Book | 1.65 |
| Price Earnings Ratio | 35.8 |
| Price To FCF | 18.54 |
| Price To sales | 2.54 |
| EV / EBITDA | 15.76 |
News
- Jan -30 - Dividends And Dynamite: 10 High-Yield Blue-Chip Bargains You Don't Want To Miss
- Jan -29 - 10 Undervalued Dividend Growth Stocks: January 2025
- Jan -29 - The RFK Jr. Effect: Biotech Stocks Brace For 'Games' In Senate Hearings
- Jan -28 - Pfizer (PFE) Stock Drops Despite Market Gains: Important Facts to Note
- Jan -28 - Pfizer Q4 Earnings Preview: 5 Critical Business Issues To Consider
- Jan -28 - PFE Stock Rises on Reports of Averting Proxy Fight With Activist Investor
- Jan -28 - Here's How to Play Pfizer Stock Before Q4 Earnings Release
- Jan -28 - Pfizer to Showcase Advancements Across Genitourinary Cancers at ASCO GU Cancers Symposium
- Jan -28 - I Own 4 High-Yield Dividend Stocks. Here's Why I Own Each One.
- Jan -27 - Pfizer's Conditionally Approved Braftovi Combo Therapy Regime Shows Improved Response In Colorectal Cancer Patients
- Jan -27 - 5 Large Cap Growth Stocks With Dividend Yields Up to 8% Are Too Cheap to Ignore
- Jan -26 - Have $500? 2 High-Yield Dividend Stocks to Buy Right Now
- Jan -25 - Inflation Just Won't Go Away: Stick With These 5 High-Yield Dividend Giants
- Jan -25 - Pfizer's BRAFTOVI® Combination Regimen Demonstrates Improved Response in Patients with BRAF V600E-Mutant Metastatic Colorectal Cancer
- Jan -25 - Is it safe to buy these high-yielding S&P 500 stocks?
- Jan -25 - Want Decades of Passive Income? 3 Stocks to Buy Now and Hold Forever.
- Jan -24 - Pfizer to pay $59.7 million over kickbacks for migraine drug
- Jan -24 - Retirees Can Count on Safe Recurring Income From These 6% Dividend Stocks
- Jan -23 - Can This Beaten-Down Stock Bounce Back in 2025?
- Jan -23 - My Top 5 Stocks to Buy in Early 2025
Business Breakdown
Expected Mid-Term Growth
Segment n°1 -> Biopharma
Expected Growth : 3.0 %
What the company do ?
Pfizer's Biopharma segment focuses on developing and commercializing innovative medicines, vaccines, and oncology products to improve patient health and well-being.
Why we expect these perspectives ?
Pfizer's Biopharma segment growth is driven by strong demand for its oncology portfolio, particularly Ibrance and Xtandi, as well as increasing sales of its vaccine portfolio, including Comirnaty. Additionally, the company's pipeline of innovative medicines and strategic partnerships are expected to contribute to future growth.
Segment n°2 -> Other Business Activities
Expected Growth : 3.0 %
What the company do ?
Pfizer's Other Business Activities include its Consumer Healthcare segment, which develops and commercializes over-the-counter (OTC) medicines and vitamins, and its Contract Manufacturing segment, which provides manufacturing services to other pharmaceutical companies.
Why we expect these perspectives ?
Pfizer's 3.0% growth in Other Business Activities is driven by increasing demand for its consumer healthcare products, expansion of its contract manufacturing business, and strategic partnerships. Additionally, the company's focus on emerging markets and e-commerce platforms has contributed to this growth.
Pfizer Inc. Products
| Product Range | What is it ? |
|---|---|
| Comirnaty | COVID-19 vaccine |
| Ibrance | Cancer treatment |
| Xeljanz | Rheumatoid arthritis treatment |
| Viagra | Erectile dysfunction treatment |
| Chantix | Smoking cessation treatment |
| Lyrica | Pain management treatment |
| Prevnar 13 | Pneumococcal conjugate vaccine |
| Xalkori | Cancer treatment |
| Sutent | Cancer treatment |
Pfizer Inc.'s Porter Forces
Threat Of Substitutes
Pfizer Inc. has a moderate threat of substitutes due to the presence of alternative treatments and generic drugs in the market.
Bargaining Power Of Customers
Pfizer Inc. has a low bargaining power of customers due to the lack of negotiating power of individual customers in the pharmaceutical industry.
Bargaining Power Of Suppliers
Pfizer Inc. has a moderate bargaining power of suppliers due to the presence of multiple suppliers of raw materials and services.
Threat Of New Entrants
Pfizer Inc. has a low threat of new entrants due to the high barriers to entry in the pharmaceutical industry, including high research and development costs and regulatory hurdles.
Intensity Of Rivalry
Pfizer Inc. operates in a highly competitive industry with many established players, leading to a high intensity of rivalry among competitors.
Capital Structure
| Value | |
|---|---|
| Debt Weight | 44.86% |
| Debt Cost | 3.95% |
| Equity Weight | 55.14% |
| Equity Cost | 6.86% |
| WACC | 5.55% |
| Leverage | 81.35% |
Pfizer Inc. : Quality Control
Pfizer Inc. passed 2 out of 9 key points:
Historical Valuation
Price/Earnings Ratio
Margin Valuation
Peers Valuation
Competitors
| Company | Rational |
|---|---|
| LLY | Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. It offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, … |
| MRK | Merck & Co., Inc. operates as a healthcare company worldwide. It operates through two segments, Pharmaceutical and Animal Health. The Pharmaceutical segment offers human health pharmaceutical products in the areas … |
| GILD | Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, … |
| BMY | Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, and markets biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, neuroscience, and covid-19 diseases. The company's products include Revlimid, … |
| BIIB | Biogen Inc. discovers, develops, manufactures, and delivers therapies for treating neurological and neurodegenerative diseases. The company offers TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI, and FAMPYRA for multiple sclerosis (MS); SPINRAZA for … |
Peers Metrics
DCF BETA
Expected Cash-Flows
Scoring Insights
Peers Group Analysis
🥇
Bristol-Myers Squibb
A-Score
1-Year Total Return ->
🥈
Pfizer
A-Score
1-Year Total Return ->
🥉
Gilead Sciences
A-Score
1-Year Total Return ->
4
Merck
A-Score
1-Year Total Return ->
5
Lilly
A-Score
1-Year Total Return ->
6
